Thus, MDM2 inhibition is potentially promising especially for MDM2 amplified tumours with wild-type p53, and MDM2 protein level is a determinant of the response to MDM2 inhibitor treatment in vitro [40, 85, 86]. Here, TP53 is linked to neoplasm.